Abstract
Abstract
Background
Tranexamic acid (TXA) is a synthetic lysine analog used for hemostasis. Inadvertent intrathecal injection of tranexamic acid (TXA) is a rare but often fatal medication error (40% mortality) characterized by profound neurotoxicity and refractory seizures. Laboratory detection of TXA in cerebrospinal fluid (CSF) may assist clinical management and toxicologic consultation; however, validated CSF assays are not routinely available. We report the rapid identification of TXA in CSF using a new mass spectrometry platform and broad-spectrum screening library.
Methods
A 49-year-old female received intrathecal TXA due to a medication order error and, after consultation with the regional Poison Center, underwent CSF lavage. Four CSF aliquots collected during the lavage procedure were submitted for toxicologic analysis. Each sample (50 µL) was diluted with 10 µL internal standard (proadifen) in 1 mL water and analyzed using a newly acquired mass spectrometer with a broad-spectrum drug screening library (Thermo Scientific Orbitrap Exploris) not previously validated for CSF TXA detection. Chromatographic retention time and mass spectral library match scores were assessed. To confirm compound identity, pharmacy-obtained TXA reference material was prepared at five concentrations (1,000–250,000 ng/mL) and analyzed using the same method for comparative evaluation.
Results
TXA was detected in all four CSF specimens. Patient sample retention times clustered tightly between 0.72–0.74 minutes, with mass spectral library match scores of approximately 90%. Reference TXA dilutions demonstrated consistent library match scores (∼90%) and retention times of 0.73–0.75 minutes. All patient and reference samples eluted within a 0.03-minute window, providing strong chromatographic concordance. The near-identical retention times and reproducible spectral match scores across patient and reference samples supported confident compound identification despite the absence of prior method validation for this matrix-analyte combination. A formal report was issued to the regional Poison Center and results were communicated to the referring institution’s Laboratory Medical Director. The patient survived the event but was discharged with persistent sequelae, specifically neuropathy and fatigue.
Conclusion
We achieved rapid TXA identification by pairing broad-spectrum mass spectrometry with a pharmacy-sourced reference standard. This case demonstrates how adaptable, high-resolution mass spectrometry provides the timely, actionable data essential for managing rare but life-threatening medication errors in acute care.